---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000142"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:58:14.744144+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M

## Summary
- Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.
- Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.
- FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.
- Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.
- Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa.

## SEC filing metadata
- accession: 0001787306-25-000142
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/0001787306-25-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/arqt-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000142
- JSON: https://secwatch.observer/filing/0001787306-25-000142.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.